Home > Research > Publications & Outputs > Cyclin-dependent kinase 12, a novel drug target...

Electronic data

  • MainText-AAM

    Rights statement: The Author's Accepted Manuscript (the accepted version of the manuscript as submitted by the author) may only be posted 6 months after the paper is published, consistent with our self-archiving embargo. Please note that the Author’s Accepted Manuscript may not be released under a Creative Commons license. For Nature Research Terms of Reuse of archived manuscripts please see: http://www.nature.com/authors/policies/license.html#terms

    Accepted author manuscript, 6.26 MB, PDF document

    Available under license: None


Text available via DOI:

View graph of relations

Cyclin-dependent kinase 12, a novel drug target for visceral leishmaniasis

Research output: Contribution to Journal/MagazineJournal articlepeer-review

  • Susan Wyllie
  • Michael Thomas
  • Stephen Patterson
  • Sabrinia Crouch
  • Manu De Rycker
  • Rhiannon Lowe
  • Stephanie Gresham
  • Thomas D. Otto
  • Laste Stojanovski
  • Frederick R. C. Simeons
  • Sujatha Manthri
  • Lorna M. MacLean
  • Fabio Zuccotto
  • Nadine Homeyer
  • Hannah Pflaumer
  • Markus Boesche
  • Lalitha Sastry
  • Paul Connolly
  • Sebastian Albrecht
  • Matt Berriman
  • Gerard Drewes
  • David W. Gray
  • Sonja Ghidelli-Disse
  • Susan Dixon
  • Jose M. Fiandor
  • Paul G. Wyatt
  • Michael A. J. Ferguson
  • Alan H. Fairlamb
  • Timothy J. Miles
  • Kevin D. Read
  • Ian H. Gilbert
<mark>Journal publication date</mark>25/07/2018
Number of pages6
Pages (from-to)192-197
Publication StatusPublished
<mark>Original language</mark>English


Visceral leishmaniasis causes considerable mortality and morbidity in many parts of the world. There is an urgent need for the development of new, effective treatments for this disease. Here we describe the development of an anti-leishmanial drug-like chemical series based on a pyrazolopyrimidine scaffold. The leading compound from this series (7, DDD853651/GSK3186899) is efficacious in a mouse model of visceral leishmaniasis, has suitable physicochemical, pharmacokinetic and toxicological properties for further development, and has been declared a preclinical candidate. Detailed mode-of-action studies indicate that compounds from this series act principally by inhibiting the parasite cdc-2-related kinase 12 (CRK12), thus defining a druggable target for visceral leishmaniasis.